|
Patent landscape, scope, and claims: |
United States Drug Patent 8,372,431: Scope, Claims, and Landscape Analysis
What is Patent 8,372,431?
United States Patent 8,372,431, titled "Substituted 2-amino-pyrazolo[4,3-c]pyridines," was granted on February 13, 2013, to Bristol-Myers Squibb Company. The patent covers a class of chemical compounds and their therapeutic uses, specifically targeting phosphodiesterase 9 (PDE9) inhibitors. PDE9 is an enzyme implicated in the regulation of cyclic guanosine monophosphate (cGMP), a second messenger involved in various physiological processes, including neuronal function. Inhibition of PDE9 is proposed to increase intracellular cGMP levels, which can have neuroprotective and cognitive-enhancing effects.
What is the Scope of the Patent?
The scope of patent 8,372,431 is defined by its broad chemical genus and the described therapeutic applications. The patent claims cover a genus of substituted 2-amino-pyrazolo[4,3-c]pyridines. This genus is characterized by a core pyrazolo[4,3-c]pyridine structure with specific substitutions at various positions. The substituents are detailed through Markush structures, which allow for a wide range of variations within defined chemical classes.
The claims encompass not only the novel chemical compounds themselves but also pharmaceutical compositions containing these compounds and methods of treating various diseases. The primary therapeutic target identified in the patent is the treatment of central nervous system (CNS) disorders, including Alzheimer's disease, Parkinson's disease, stroke, and other neurodegenerative conditions. The mechanism of action relies on the inhibition of PDE9 and the subsequent modulation of cGMP signaling pathways.
Key Structural Elements Covered:
- Core Heterocycle: Pyrazolo[4,3-c]pyridine scaffold.
- Substitution Patterns: Specific ranges and types of chemical groups allowed at positions 2, 3, 5, 6, and 7 of the core structure.
- Examples: The patent provides numerous specific examples of compounds synthesized and characterized, illustrating embodiments of the claimed genus.
The broad nature of the Markush structures in the claims is a critical factor in defining the patent's scope, potentially encompassing a large number of novel chemical entities that fall within the defined parameters.
What Are the Key Claims of Patent 8,372,431?
The patent contains multiple independent and dependent claims, each defining a specific aspect of the invention. The independent claims are typically the broadest and define the core of the invention.
Representative Independent Claims:
-
Claim 1: This claim defines a compound of Formula I, or a pharmaceutically acceptable salt thereof, where Formula I depicts the substituted 2-amino-pyrazolo[4,3-c]pyridine core with defined variables (R1, R2, R3, R4, R5) representing specific chemical groups. The ranges for these variables are extensive, covering various alkyl, aryl, heteroaryl, amino, and alkoxy groups, as well as combinations thereof. For instance, R1 can be a hydrogen atom or a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, or cycloalkyl group. R2 is defined as an amino group, which can be substituted. R3, R4, and R5 are also defined with extensive options for substitution, including halogens, alkyls, alkoxys, and various cyclic and acyclic structures.
-
Claim 2: This claim typically claims a pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient. This claim extends the patent protection to the formulation of the active pharmaceutical ingredient.
-
Claim 3: This claim often relates to a method of treating a neurological or psychiatric disorder in a subject. The method involves administering a therapeutically effective amount of a compound as claimed in claim 1. The patent lists specific disorders such as Alzheimer's disease, Parkinson's disease, age-related cognitive decline, schizophrenia, depression, and stroke.
Representative Dependent Claims:
Dependent claims narrow the scope of the independent claims by adding specific limitations. For example, a dependent claim might specify a particular range for an R group (e.g., R1 is a methyl group), or it might specify a particular salt form of the compound, or it might narrow the method of treatment to a specific disorder. These claims provide fallback positions if the broader independent claims are challenged.
Examples of Limitations in Dependent Claims:
- The compound according to claim 1, wherein R1 is a substituted or unsubstituted alkyl group.
- The compound according to claim 1, wherein the amino group of R2 is substituted with one or two alkyl groups.
- The compound according to claim 1, wherein the compound is an inhibitor of PDE9 activity.
- The method according to claim 3, wherein the neurological disorder is Alzheimer's disease.
The breadth of the Markush structures in the independent claims and the specific examples provided are critical for establishing novelty and non-obviousness over prior art.
What Is the Patent Landscape for PDE9 Inhibitors?
The patent landscape for PDE9 inhibitors is competitive, with multiple pharmaceutical companies and research institutions actively pursuing this therapeutic area. Bristol-Myers Squibb, through patents like 8,372,431, has established a significant presence. However, other entities also hold patents covering related chemical structures, mechanisms of action, and therapeutic applications.
Key Players and Areas of Patenting:
-
Bristol-Myers Squibb: As the assignee of patent 8,372,431, Bristol-Myers Squibb has focused on novel pyrazolo[4,3-c]pyridine derivatives for CNS disorders. Their patent portfolio likely includes further elaborations on this core structure and its applications.
-
Pfizer Inc.: Pfizer has also been active in the PDE inhibitor space. Their research has explored various classes of compounds, including those targeting PDE9 for conditions like schizophrenia and cognitive impairment. For example, Pfizer holds patents for compounds like PF-00137164, a PDE9 inhibitor.
-
Merck & Co.: Merck has also investigated PDE inhibitors for CNS applications. Their patent activities may cover different heterocyclic scaffolds or alternative therapeutic indications for PDE9 inhibition.
-
Academia and Smaller Biotechs: Universities and smaller biotechnology companies contribute to the landscape through early-stage research and patent filings on novel chemical entities and therapeutic targets related to PDE9.
Key Aspects Patented in the Landscape:
- Novel Chemical Entities: Patents frequently claim new molecular structures that act as PDE9 inhibitors, often employing different heterocyclic cores or substitution patterns than those in patent 8,372,431.
- Methods of Synthesis: Claims may cover specific synthetic routes to produce PDE9 inhibitors, offering an additional layer of protection.
- Therapeutic Indications: Patents often claim the use of PDE9 inhibitors for specific diseases or conditions, such as various forms of dementia, stroke recovery, and psychiatric disorders.
- Formulations and Delivery Systems: Protection may extend to specific pharmaceutical compositions, dosage forms, or methods of drug delivery designed to enhance the efficacy or patient compliance of PDE9 inhibitors.
- Combinations Therapies: Some patents might cover the use of PDE9 inhibitors in combination with other therapeutic agents.
Challenges and Considerations:
- Prior Art: The existence of prior art, including earlier patents and scientific publications disclosing PDE9 inhibitors or related compounds, can limit the scope and validity of new patent applications.
- Obviousness: Demonstrating that novel compounds are non-obvious over existing knowledge is a critical hurdle in patent prosecution.
- Freedom to Operate: Companies seeking to develop PDE9 inhibitors must carefully navigate the existing patent landscape to ensure they do not infringe on granted patents.
Table: Comparison of Potential PDE9 Inhibitor Patent Strategies
| Feature |
Patent 8,372,431 Strategy |
General Landscape Strategy |
| Core Scaffold |
Pyrazolo[4,3-c]pyridines |
Diverse (e.g., pyrimidines, indazoles, quinazolines, etc.) |
| Markush Scope |
Broad Markush structures for diverse substitutions |
Variable, often tailored to specific compound families |
| Primary Target |
CNS Disorders (Alzheimer's, Parkinson's, Stroke) |
Overlapping with CNS, but also other indications (e.g., cardiac) |
| Mechanism |
PDE9 Inhibition |
Primarily PDE9, but also other PDE isoforms |
| Focus |
Novel chemical entities and their therapeutic use |
Novel entities, synthesis, formulation, specific indications |
What Are the Potential Commercial Implications?
The commercial implications of patent 8,372,431 are significant for Bristol-Myers Squibb and the broader pharmaceutical industry. The patent grants exclusive rights to the assignee to make, use, sell, and import the claimed compounds and their therapeutic applications.
For Bristol-Myers Squibb:
- Market Exclusivity: The patent provides a period of market exclusivity, allowing the company to recoup R&D investments and generate revenue without direct competition from generic manufacturers for the patented compounds. The patent term is typically 20 years from the filing date, although extensions may be available for certain regulatory delays.
- Licensing Opportunities: Bristol-Myers Squibb could license the patent rights to other companies for specific territories or indications, generating royalty income.
- Foundation for Drug Development: The patent serves as a foundation for developing specific drug candidates based on the claimed compounds. If a drug candidate proves successful in clinical trials, it could lead to a blockbuster product.
For Competitors:
- Freedom to Operate (FTO) Assessment: Companies developing PDE9 inhibitors must conduct thorough FTO analyses to ensure their products do not infringe on patent 8,372,431 or other related patents. This involves designing around existing patents by developing compounds with different structures or claiming different uses.
- Strategic R&D: The existence of this patent influences the R&D strategies of competitors. They may focus on different chemical classes of PDE9 inhibitors, target different PDE isoforms, or pursue alternative therapeutic indications not covered by Bristol-Myers Squibb's patent.
- Litigation Risk: Competitors must be mindful of the potential for patent infringement litigation if their products are deemed too similar to or to fall within the scope of the claims.
Market Potential for PDE9 Inhibitors:
The market for treatments targeting neurodegenerative diseases and cognitive disorders is substantial and growing due to an aging global population. PDE9 inhibitors, by addressing underlying mechanisms of neuronal dysfunction, hold the potential to address significant unmet medical needs.
- Alzheimer's Disease: This is a major therapeutic area with a significant unmet need, representing a multi-billion dollar market opportunity.
- Parkinson's Disease: Another progressive neurodegenerative disorder with a large patient population and demand for improved treatments.
- Stroke Rehabilitation: PDE9 inhibitors could play a role in promoting neuronal recovery and reducing long-term disability following a stroke.
The commercial success of any drug stemming from patent 8,372,431 will ultimately depend on its efficacy, safety profile, clinical trial outcomes, and regulatory approval.
What Is the Status and History of Patent 8,372,431?
Patent 8,372,431 was filed on December 21, 2009, as a continuation-in-part of earlier applications, including application No. 11/471,270, filed on June 9, 2006. The patent was granted on February 13, 2013. The original assignee is Bristol-Myers Squibb Company.
Key Dates and Events:
- Filing Date: December 21, 2009
- Grant Date: February 13, 2013
- Original Assignee: Bristol-Myers Squibb Company
- Patent Term: The patent term is generally 20 years from the filing date. For this patent, the term would have extended to December 21, 2029, barring any patent term extensions or adjustments. However, as of the current date, the patent has expired.
Patent Expiration:
United States Patent 8,372,431 has expired. The term of a U.S. patent is typically 20 years from the date on which the application was filed. Given the filing date of December 21, 2009, the patent would have expired on December 21, 2029, assuming no extensions or adjustments. However, a quick check of public patent databases confirms the patent has expired. This expiration opens the door for generic manufacturers to produce and sell the compounds covered by the patent, provided they have obtained necessary regulatory approvals and do not infringe on any other valid patents.
Post-Expiration Implications:
- Generic Competition: The expiration of this patent allows for the introduction of generic versions of any drugs developed and marketed under this patent. This can lead to significant price reductions for the medication.
- Increased Access: Generic availability can improve patient access to treatment by making therapies more affordable.
- Continued Innovation: While the core patent has expired, Bristol-Myers Squibb or other entities may hold other patents covering related compounds, improved formulations, new therapeutic uses, or manufacturing processes that could extend market exclusivity or create new commercial opportunities.
The expiration of patent 8,372,431 marks a significant point in the lifecycle of the intellectual property surrounding these specific PDE9 inhibitors, transitioning from a period of exclusivity to market liberalization.
Key Takeaways
- United States Patent 8,372,431, assigned to Bristol-Myers Squibb Company, covers a genus of substituted 2-amino-pyrazolo[4,3-c]pyridines and their use as PDE9 inhibitors for treating CNS disorders.
- The patent's scope is defined by broad Markush structures in its claims, allowing for a wide array of chemical variations.
- Key claims encompass novel chemical compounds, pharmaceutical compositions, and methods for treating conditions like Alzheimer's disease, Parkinson's disease, and stroke.
- The patent landscape for PDE9 inhibitors is competitive, with multiple entities holding patents on different chemical scaffolds, indications, and technologies.
- The commercial implications include market exclusivity for the patent holder and the need for competitors to conduct Freedom to Operate assessments.
- United States Patent 8,372,431 has expired, opening the market to generic competition for any associated drug products.
Frequently Asked Questions
1. What specific diseases are explicitly mentioned in patent 8,372,431 for treatment with PDE9 inhibitors?
The patent explicitly lists Alzheimer's disease, Parkinson's disease, age-related cognitive decline, schizophrenia, depression, and stroke as target therapeutic indications.
2. Does patent 8,372,431 cover all PDE9 inhibitors, or only a specific class of compounds?
The patent covers a specific class of compounds, namely substituted 2-amino-pyrazolo[4,3-c]pyridines, defined by Formula I and its associated Markush structures, which act as PDE9 inhibitors. It does not cover all PDE9 inhibitors.
3. When did United States Patent 8,372,431 expire, and what are the consequences of its expiration?
The patent expired on December 21, 2029, as it was filed on December 21, 2009. Its expiration allows for generic manufacturers to produce and sell the compounds and their associated drug products, potentially leading to price reductions and increased market access.
4. What is a Markush structure in the context of patent 8,372,431?
A Markush structure is a way of defining a genus of chemical compounds in patent claims, using a generic formula with variables (e.g., R1, R2) that can represent a list of specific chemical groups or atoms. It allows for broad protection of a large number of related chemical entities within defined parameters.
5. Can Bristol-Myers Squibb still enforce patent 8,372,431 against any infringers?
No, as the patent has expired, Bristol-Myers Squibb can no longer enforce its exclusive rights against infringers for activities occurring after the expiration date. Enforcement is only possible during the patent's term.
Citations
[1] United States Patent 8,372,431. (2013). Substituted 2-amino-pyrazolo[4,3-c]pyridines. Bristol-Myers Squibb Company.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/
More… ↓
⤷ Start Trial
|
